| abstract |
The present invention provides compositions and methods for treating diseases associated with the expression of EGFRvIII. The invention also relates to a recombinant T cell comprising a chimeric antigen receptor (CAR) specific for EGFRvIII, a vector encoding the same, and anti-EGFRvIII CAR. The invention also encompasses methods of administering genetically modified T cells expressing CAR comprising an anti-EGFRvIII binding domain. |